Caris Precision Oncology Alliance

Caris POA Members & Locations

The Caris POA includes more than 95 leading cancer institutions and research consortia, including over 45 NCI-designated comprehensive cancer centers, collaborating to deliver molecular science solutions that promote clinical trials, deliver combined clinical-genomic data, and advance collaborative research and publications.

Caris POA Leadership

The Caris POA Executive Committee establishes appropriate molecular testing principles to serve as guidelines for the consistent application of tumor profiling across the oncology community. Responsible for facilitating collaborative research studies across the Caris POA and coordinating outcome tracking initiatives, the Committee helps to generate and document additional medical evidence for the appropriate use and impact of profiling. 

Manmeet Ahluwalia, MD, MBA

Chief, Solid Tumor Medical Oncology
Deputy Director, Chief Scientific Officer
Miami Cancer Institute

Heinz-Josef Lenz, MD, FACP

Associate Director for Clinical Research
USC Norris Comprehensive Cancer Center

Sagar Lonial, MD, FACP

Chief Medical Officer
Professor and Chair
Emory University

Marcia Cruz-Correa, MD, PhD

Executive Director
University of Puerto Rico

Ruben Mesa, MD

President / Executive Director
Atrium Health
Levine Cancer / Wake Forest

John L. Marshall, MD

Chief, Hematology and Oncology
Georgetown University

Thomas Herzog, MD

Professor of OB-GYN
Deputy Director
University of Cincinnati Cancer Institute

Wafik El-Deiry, MD, PhD, FACP

Associate Dean for Oncologic Sciences
Brown University

Resources that Empower POA Members

At the forefront of molecular science and artificial intelligence, Caris Life Sciences is deeply committed to bringing the vision of precision medicine to life. Caris achieves this by delivering advanced diagnostic testing and crucial molecular insights, enabling POA partners to enhance cancer care and improve patient outcomes. With a distinctive blend of expertise, proprietary technologies, and a vast data repository, Caris collaborates with the POA, charting innovative courses in precision medicine.

Caris CODEai

Delivers value through a growing database with over 295,000 clinical outcomes paired with matched molecular data.

Research Initiation
(Letter of Intent Process)

Engaging with Caris often involves proposing and initiating collaborative research projects within the POA membership for advancing research efforts.

Molecular Minute
Podcast Series

Gain valuable insights from today’s foremost oncology experts on a wide array of leading-edge subjects in precision oncology and the evolution of cancer care.

Publications

The POA continues to amplify the significance of biomarker analysis and tumor profiling in cancer care, fostering a deeper understanding of molecular science and propelling the evolution of precision medicine through its publications.

Caris Molecular Tumor Board

Facilitates collaboration between clinicians and top oncologists to analyze complex molecular data, providing tailored therapeutic recommendations and support for challenging cancer cases.

Right-In-Time Trials

Caris’ Right-In-Time clinical trial network eliminates repetitive contracting, feasibility and site qualification activities so providers can focus on treating their patients, rather than the administrative burden of clinical trial start-up.